A spokesman for the New York state-based Regeneron, who identified himself only as Alex, said the U.S. government owns the currently available supply of REGEN-COV, which is the company’s monoclonal antibody treatment. The U.S. government allocates that product to state governments.
“We do not sell the medicine commercially at this point,” Alex said.